2018 ´ëÇѺÎÀξÏÁß°³¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö : 2018-10-28±³À°ÀÏÀÚ : 2018-10-28
±³À°Àå¼Ò : ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ´ë°´ç
±³À°ÁÖÁ¦ :
2018 ´ëÇѺÎÀξÏÁß°³¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö ÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸
´ã´çÀÚ : ½ÅÁÖÇö
¿¬¶ôó : 053-250-7599
À̸ÞÀÏ :
kgcr-km@naver.com ±³À°Á¾·ù : »êºÎÀΰú»ý¸®ÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ, ¾à¸®ÇÐ
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 10,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10¿ù 28ÀÏ ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ ´ë°´ç 09:15~09:45 nc886 as a potential oncogenic driver in ovarian cancer ÃÖÁ¤Çý(°æÈñ´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ ´ë°´ç 09:45~10:15 Understanding single cell analysis and recent status. ±èÁø¿µ(°è¸í´ë)
Åä·Ð 10¿ù 28ÀÏ ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ ´ë°´ç 10:15~10:25 Áú¹® ¹× ÅäÀÇ ()
ÈÞ½Ä 10¿ù 28ÀÏ ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ ´ë°´ç 10:25~10:45 Coffee break ()
±³À°½Ã°£ 10¿ù 28ÀÏ ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ ´ë°´ç 10:45~11:15 Suppressive role of elevated estrogen on endometrial carcinogenesis Tanri Shiozawa(Shinshu University School of Medicine)
Åä·Ð 10¿ù 28ÀÏ ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ ´ë°´ç 11:15~11:25 Áú¹® ¹× ÅäÀÇ ()
±³À°½Ã°£ 10¿ù 28ÀÏ ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ ´ë°´ç 11:25~11:45 Clinical application of NGS in Gynecologic malignancy Á¤Çý¶ó(°è¸í´ë)
ÈÞ½Ä 10¿ù 28ÀÏ ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ ´ë°´ç 11:45~12:45 Lunch ()
±³À°½Ã°£ 10¿ù 28ÀÏ ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ ´ë°´ç 12:45~13:15 Dissecting cellular heterogeneity using single-cell RNA sequencing ±èÁ¾°æ ¹Ú»ç(DGIST)
Åä·Ð 10¿ù 28ÀÏ ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ ´ë°´ç 13:15~13:25 Áú¹® ¹× ÅäÀÇ ()
±³À°½Ã°£ 10¿ù 28ÀÏ ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ ´ë°´ç 13:25~13:50 Reverse Engineering Personalized Cancer Therapies: Finding the Disease to Fit the Drug ±èÇö¼®(¿¬¼¼´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ ´ë°´ç 13:50~14:15 Application of single cell RNA sequencing for cancer ÀÌÇý¿Á(»ï¼º À¯Àüü ¿¬±¸¼Ò)
Åä·Ð 10¿ù 28ÀÏ ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ ´ë°´ç 14:15~14:25 Áö¸íÅäÀÇ À̽ÅÈ(¿ï»ê´ë)
ÈÞ½Ä 10¿ù 28ÀÏ ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ ´ë°´ç 14:25~14:45 Coffee break ()
±³À°½Ã°£ 10¿ù 28ÀÏ ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ ´ë°´ç 14:45~15:05 Combination effects of PARP and DNMT inhibitors in EOC Á¤¼ö¿µ(¼º±Õ°ü´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ ´ë°´ç 15:05~15:25 Ovarian tissue cryopreservation and xenotransplantation ÀÌ»óÈÆ(°í·Á´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ ´ë°´ç 15:25~15:45 Translational research in Ovarian cancer (Genomics and Cancer metabolism) ¾ç¿ì°â(¿¬¼¼´ë)
Åä·Ð 10¿ù 28ÀÏ ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ ´ë°´ç 15:45~15:55 Áú¹® ¹× ÅäÀÇ ()
±³À°½Ã°£ 10¿ù 28ÀÏ ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ ´ë°´ç 15:55~16:05 Epigenetic loss of ATP5H promotes multi-modal cancer therapy resistance through mitochondrial reprogramming ¼Û±ÇÈ£(°í·Á´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ ´ë°´ç 16:05~16:15 Adoptive cell therapy using tumor-reactive T cells at NCC ÃÖ¹ü±Ô(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 10¿ù 28ÀÏ ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ ´ë°´ç 16:15~16:25 Inhibitory Effect of Wnt/¥â-Catenin Inhibitor CWP232228 on the Growth of Ovarian Cancer Cells À̽¹Ì(°è¸í´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ ´ë°´ç 16:25~16:35 Clinical Impact of Mismatch repair deficiency in endometrial cancer Àü¼·(¼øõÇâ´ë)
±³À°½Ã°£ 10¿ù 28ÀÏ ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ ´ë°´ç 16:35~16:45 Oncolytic efficacy of reovirus against ovarian cancer ¿À¿µÅÃ(°í·Á´ë ±¸·Îº´¿ø)
±³À°½Ã°£ 10¿ù 28ÀÏ ¼¿ï¾Æ»êº´¿ø ¿¬±¸¿ø ÁöÇÏ ´ë°´ç 16:45~16:55 Àå¾×¼º ³¼Ò¾Ï Ç÷¾× ´ë»çü¿Í ´Ü¹éü ¿¬±¸¸¦ ÅëÇÑ Áø´Ü ¹ÙÀÌ¿À¸¶Ä¿ °³¹ß ¿À¼Ò¹Ì(°³²±Ç»êºÎÀΰú)